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chestjournal.orgBACKGROUND: Noninvasive ventilation (NIV) is standard of care for chronic hypercapnic
respiratory failure, but indications, devices, and ventilatory modes are in constant evolution.
RESEARCH QUESTION: To describe changes in prevalence and indications for NIV over a 15-year
period; to provide a comprehensive report of characteristics of the population treated (age,
comorbidities, and anthropometric data), mode of implementation and follow-up, devices,
modes and settings used, physiological data, compliance, and data from ventilator software.
STUDY DESIGN AND METHODS: Cross-sectional observational study designed to include all
subjects under NIV followed by all structures involved in NIV in the Cantons of Geneva and
Vaud (1,288,378 inhabitants).
RESULTS: A total of 489 patients under NIV were included. Prevalence increased 2.5-fold since
2000 reaching 38 per 100,000 inhabitants. Median age was 71 years, with 31% being> 75 years
of age. Patients had been under NIV for a median of 39 months and had an average of 3 1.8
comorbidities; 55% were obese. COPD (including overlap syndrome) was the most important
patient group, followed by obesity hypoventilation syndrome (OHS) (26%). Daytime PaCO2
was most often normalized. Adherence to treatment was satisfactory, with 8% only using their
device < 3.5 h/d. Bilevel positive pressure ventilators in spontaneous/timed mode was the
default mode (86%), with a low use of autotitrating modes. NIV was initiated electively in
50% of the population, in a hospital setting in 82%, and as outpatients in 15%.
INTERPRETATION: Use of NIV is increasing rapidly in this area, and the population treated is
aging, comorbid, and frequently obese. COPD is presently the leading indication followed byOHS.
TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT04054570; URL: www.clinicaltrials.gov
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Noninvasive ventilation (NIV) is accepted as standard of
care for chronic hypercapnic respiratory failure. NIV
appeared in Western Europe and in the United States in
the mid-1980s shortly after the advent of CPAP for severe
OSA syndrome (OSAS).1,2 Ventilators used for home
ventilation were initially volume-cycled devices.3 Amajor
breakthrough in chronic NIV was the advent of a simple
bilevel positive pressure ventilator device for home use
commercialized in 1990.4,5 During the 1990s, pressure-
cycled ventilators progressively replaced the more
cumbersome, expensive, and less comfortable volume-
cycled devices.3
Over the past 15 years, home ventilators have undergone
major technical evolutions; however, sometimes they are
of undetermined clinical relevance.6-8 Volume-assured
pressure support, autotitrating expiratory positive
airway pressure (EPAP), inspiratory positive airway
pressure (IPAP), pressure support, backup rates, and
built-in algorithms profiled for certain pathologies are
now standard options on many ventilators.9-15 More
importantly, built-in software provides important
information for monitoring efficacy of NIV (ie,
estimation of leaks, tidal volume, residual respiratory
events, percentage of cycles triggered and cycled by the
ventilator, compliance).16,17Lausanne University Hospital (CHUV), Lausanne, Switzerland; the
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280 Original ResearchThe population of patients under chronic NIV has also
changed, from the initial predominantly restrictive
indications (sequelae of TB, postpolio syndrome, chest
wall disorders, and neuromuscular disorders) to a
progressive increase of patients with chronic respiratory
failure (CRF) because of obesity hypoventilation
syndrome (OHS), COPD, and overlap syndromes which
started in the late 1990s.3,18,19
Fifteen years after our initial cohort study,3 this
report provides a comprehensive description of all
patients under home mechanical ventilation in the
Cantons of Geneva and Vaud, an area covering a
population of around 1.3 million inhabitants. The
aims of this study were as follows: (1) to detail
present indications for NIV, their relative
importance, and the prevalence of its use; (2) to
describe the population under NIV, and its major
comorbidities; (3) to compare prevalence of NIV and
indications with data previously published by our
group covering the same area and population 15
years ago; and (4) to provide detailed data on
settings, compliance, correction of respiratory events
and other items reported by ventilator software, and
modalities of medical follow-up.Patients and Methods
Study Design
A cross-sectional observational study was designed to include all
subjects under NIV followed by every possible structure involved in
NIV in the Cantons of Geneva and Vaud (1,288,378 inhabitants in
2017): university hospitals, regional general hospitals, pulmonary
rehabilitation centers, and pulmonologists in private practice.
Prevalence was compared with data previously published by our
group covering the same area and population in 2000.3In Switzerland, home mechanical ventilation can be prescribed,
initiated, and followed by pulmonologists in private practice without
referral to an expert center.
Ethical Approval
Ethical approval was granted by the Cantonal Commission for
Research Ethics in Geneva, Switzerland (No. PB_2016-00925/15-275)
in agreement with the amended Declaration of Helsinki. The trial
was registered at clinicaltrials.gov (No. NCT04054570). Identification,
screening, and data collection were performed by two investigators
between June 1, 2016, and July 10, 2018.
Inclusion/Exclusion Criteria
This study focuses exclusively on patients treated by pressure-cycled,
multimodal, and volume-cycled home ventilators, excluding adaptive
servo-ventilation (ASV), at home or in a long-term care facility (not
a hospital) for $ 3 months. Patients were excluded if they used any
other device, if they refused data collection regarding their home
NIV, or if their pulmonologist refused to participate in this study.
Data Collected
Anthropometric data, diagnoses leading to NIV, a list of predefined
major comorbidities, pulmonary function tests, arterial blood gases
(ABGs), pulse oximetry, transcutaneous capnography, type of NIV
devices, settings, interfaces, and reports downloaded from devices
were collected from medical records. Modalities of implementation
of NIV (elective vs emergency, outpatient vs inpatient, by a hospital
vs a pulmonologist) and follow-up were also collected. No additional
investigation was performed by the investigators. Availability of
recent pulmonary function tests, ABGs, pulse-oximetry, and[ 1 5 8 # 1 CHE S T J U L Y 2 0 2 0 ]
capnography depended on real-life follow-up procedures and medical
records. ABG measurements were all performed without NIV and are
follow-up values. Data recorded were the most recent measurements
performed within the 12 months prior to data collection. Tests
which had not been performed within the previous 12 months were
considered as missing.
To ensure that data collected were comprehensive, we cross-checked
lists provided by all health-care providers in our area, ventilator
manufacturers, and hospitals involved. Screening and data collection
started on June 1, 2016, and ended on July 10, 2018.
Diagnostic Categories
Diagnostic and functional criteria used for determining indication for
NIV were always determined by pulmonologists either electively, or
after an acute episode of hypercapnic respiratory failure (this is a
prerequisite for reimbursement).
For all patients, indication for implementing NIV was based on the
1999 Consensus Conference Report.20 Patients with COPD had
persistent airflow limitation with a documented FEV1/FVC < 70%
after bronchodilation (according to www.goldcopd.org criteria). NIV
was implemented if patients with COPD were hypercapnic (> 7.3 kPa
or 55 mm Hg) in a stable condition, if they remained hypercapnic
after an acute episode of hypercapnic respiratory failure, or if
they were hypercapnic (50-54 mm Hg) and had repeated episodes
of acute episode of hypercapnic respiratory failure ($ 2) within
the preceding year. Patients with overlap syndrome had COPD and
OSAS. Patients with OHS, defined as the combined presence of
obesity (BMI > 30 kg/m2) and daytime hypercapnia in the absence
of any other causes of restrictive or obstructive pulmonary1,014 patients under home NIV
screened between June 1, 2016
and December 20, 2017
in the Geneva Lake area
489 patients under NIV
947 patients under home NIV
Figure 1 – Flowchart. NIV ¼ noninvasive ventilation.
chestjournal.orgdisorder, were treated by NIV when PaCO2 was > 45 mm Hg.
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Details regarding neuromuscular diseases (NMDs), kyphoscoliosis
(KYPH), other restrictive lung disorders (RLDs), and sleep-related
breathing disorders (SRBDs) are provided in Table 2 and e-Table 2.
For patients with RLDs and KYPH, NIV was initiated in the
presence of symptoms and a daytime PaCO2 > 45mm Hg. For patients
with SRBDs, NIV was most often implemented after failure of CPAP
or ASV.
Sleep studies are not mandatory for indications such as RLDs, KYPH,
or COPD without overlap syndrome. Respiratory polygraphy or
polysomnography are usually performed in patients with OHS,
SRBD, and overlap syndrome.
Statistical Analysis
Qualitative data were described as frequencies and percentages, and
quantitative data were described as medians and interquartile ranges
(IQRs (25th-75th percentiles) or means and SDs as appropriate.
Association between choice of interface and apnea-hypopnea index
(AHI) was assessed using a simple linear regression model. Mean
differences of number of comorbidities, average daily use of
ventilator, and correction of SRDBs between subjects with a hospital-
based or a liberal pulmonologist-based follow-up were assessed using
Welch and Student t tests. A multivariable linear regression model
was used to investigate the effect of potential factors impacting on
the average daily use of NIV.
Missing data were simply reported as a modality of follow-up reflecting
real-life practices. All analyses were performed on a two-sided alpha
level of 0.05.Results
Two university hospitals, one regional general hospital,
one pulmonary rehabilitation center, and 38 of the 43
pulmonologists in private practice in the Cantons of
Geneva and Vaud participated in data collection (ie, allpossible structures and specialists involved, albeit for five
pulmonologists).
Of the 1,014 patients identified as being treated by home
NIV during the data collection period, 489 patients
under NIV were included in this analysis (Fig 1).Patients refused data collection:
n = 30 excluded
Pulmonologists refused data collection:
n = 26 cases excluded
Patients ventilated invasively
n = 11 excluded
458 patients under adaptive servo-
ventilation (ASV) excluded from present
analysis
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Patients under ASV (n ¼ 458) and patients who were
ventilated by tracheostomy (n ¼ 11) were excluded (this
number has remained stable over the past 15 years).
Based on a population of 1,288,378 inhabitants at the
end of 2017 in this area, prevalence of NIV can be
estimated at 37.9 per 100,000 inhabitants. This
represents a 2.5-fold increase when compared with the
154 patients under NIV in the same area in 2000 (ie, a
prevalence of 15.1 per 100,000 inhabitants).3 Changes in
diagnostic categories since 2000 are shown in Figure 2.
Details of these changes are provided in e-Table 1.
Study Population and Comorbidities
Details as to specific diagnoses of patient groups
included in Tables 1 and 3-5 are provided in Tables 2
and e-Table 2.
Median age (71 years; IQR, 59-77) was rather high: 151
subjects (31%) were $ 75 years of age and 88 (18%)
were $ 80 years of age. There was a slight male
predominance (n ¼ 272; 56%). The youngest group was
that of patients with NMDs.
Patients had been under NIV for a median of 39 months
(IQR, 14-73).
Comorbidities and their respective prevalence are shown
in Table 1 and e-Figure 1. On average, patients had 3.0
 1.8 comorbidities: 91% had at least one comorbidity,























n = 154 n = 489
Figure 2 – Evolution of indications for noninvasive ventilation in the
Geneva Lake area between 2000 (n ¼ 154) and 2018 (n ¼ 489). COPD
includes overlap syndrome. KYPH ¼ kyphoscoliosis; NMD ¼ neuro-
muscular disorders; OHS ¼ obesity hypoventilation syndrome; RLD ¼
restrictive lung disorder; SRBD ¼ sleep-related breathing disorders.
282 Original Researchmore comorbidities. Systemic hypertension (n ¼ 334;
68%) was the most frequent comorbidity reported.
Obesity was highly prevalent: BMI was $ 30 kg/m2 in
270 patients (55%), $ 35 kg/m2 in 180 patients (37%),
and $ 40 kg/m2 in 106 patients (22%).
Functional Tests, Nocturnal Pulse Oximetry, and
Nocturnal Capnography
Results of spirometry, ABGs, nocturnal pulse oximetry,
and nocturnal capnography are shown in Table 3.
Distribution of values of daytime PaCO2 is shown in
e-Figure 2. ABGs reported were performed without NIV.
Most patients were normocapnic. However, daytime
PaCO2 was $ 6 kPa in 170 patients (46%), $ 6.5 kPa in
99 patients (27%), and $ 7 kPa in 63 subjects (17%).
Mean nocturnal pulse oximeter oxygen saturation
was $ 90% in 279 patients (80% of the 350 tracings
available).
Ventilators
Devices used are listed in e-Table 3. Devices were mostly
bilevel positive pressure devices (n ¼ 478, 98%). Eleven
patients (2%) had multimodal ventilators. Use of
humidifiers and oxygen supplementation is reported in
Table 4.
Modes and Settings
Most patients (n ¼ 407; 86%) used a bilevel positive
pressure device in a spontaneous/timed mode (ie, with
fixed levels of positive end-expiratory pressure and
pressure support and a backup respiratory rate). In this
mode, the patient triggers the ventilator, and controlled
cycles are provided only when the patients’ respiratory
rate drops under the preset backup respiratory rate (Fig
3A). None of the subjects included used a spontaneous
or controlled mode. Volume-targeted (n ¼ 49, 12%;
iVAPS [ResMed]; AVAPS-AE [Philips Respironics])
and other autotitrating modes (n ¼ 19, 5%) were used
infrequently. Multimodal ventilators (n ¼ 11, 2%) were
used in either volume assist-control, pressure control, or
pressure support modes, exclusively in restrictive
disorders (NMDs, KYPH, and other restrictive
disorders) (Table 5, e-Table 6).
Patients with OHS and overlap syndrome had the
highest values for IPAP and EPAP. Details of the
settings are provided in Table 4.
Interfaces
Facial masks were the most frequently used interfaces
(n ¼ 358, 73%), followed by nasal masks (n ¼ 91, 19%)
and nasal pillows (n ¼ 40, 8%) (Fig 3B, Table 4).[ 1 5 8 # 1 CHE S T J U L Y 2 0 2 0 ]
TABLE 1 ] Characteristics of Patients Under Noninvasive Ventilation and Major Comorbidities







No. (%) 489 (100) 135 (28) 55 (11) 79 (16) 127 (26) 29 (6) 22 (4) 42 (9)
Age, y 71 (59-77) 72 (67-78) 71 (65-81) 59 (41-73) 69 (59-77) 69 (53-79) 73 (64-78) 65 (51-74)
Sex, male 272 (56) 68 (50) 36 (65) 45 (57) 60 (47) 12 (41) 14 (64) 37 (88)
BMI, kg/m2 31 (24-39) 28 (21-33) 32 (28-40) 24 (19-28) 41 (37-47)a 25 (19-32) 24 (19-29) 30 (27-35)
Time under NIV, mo 39 (14-73) 23 (9-48) 43 (19-73) 40 (12-105) 44 (20-78) 60 (26-133) 65 (35-109) 39 (9-91)
Comorbidities
Systemic hypertension 334 (68) 91 (67) 46 (84) 31 (39) 104 (82) 18 (64)a 16 (73) 28 (67)
Obesity 271 (55) 52 (38) 38 (69) 16 (20) 127 (100) 11 (38) 4 (18) 22 (52)
Anxiety and/or depressive disorder 220 (45) 82 (17) 16 (29) 27 (34) 68 (53) 8 (28) 7 (32) 12 (29)
Dyslipidemia 209 (43) 56 (41) 28 (51) 16 (20) 73 (57) 12 (43)a 7 (32) 17 (40)
Type 2 diabetes 149 (30) 22 (16) 20 (36) 10 (13) 76 (60) 4 (14)a 6 (27) 11 (26)
Chronic heart failure 106 (22) 29 (21) 15 (27) 11 (14) 36 (28) 3 (11)a 7 (32) 5 (12)
Pulmonary hypertension 86 (18) 36 (27) 16 (29) 4 (5) 18 (14) 6 (21)a 5 (23) 1 (2)
Cerebrovascular disease 26 (5) 9 (7) 5 (9) 2 (2) 7 (5) 0 (0)a 1 (4) 2 (3)
Treatment with opiates 17 (3) 6 (4.4) 1 (2) 0 (0) 2 (2) 0 (0) 0 (0) 8 (19)
Values listed are the most recent values obtained. Values are expressed as median (interquartile range) or No. (%). NIV ¼ noninvasive ventilation; OHS ¼ obesity hypoventilation syndrome; SRBD ¼ sleep-related
breathing disorder.










TABLE 2 ] Specific Diagnoses for Patients With
Neuromuscular Disorders, Restrictive Lung





Congenital muscular dystrophies 14 (18)
Congenital myopathies 4 (5)
Myotonic muscular dystrophies 13 (16)
Amyotrophic lateral sclerosis 15 (19)
Phrenic nerve paralysis (unilateral and/or
bilateral)
14 (18)
Brainstem or cervical cord injury 6 (8)




Myasthenia gravis 3 (4)
Missing data 1
Other restrictive disorders 22
Postpolio syndrome 9 (41)
Sequelae of thoracic surgery 5 (23)
End-stage pulmonary fibrosis 5 (23)
Bronchiectasis 2 (9)
Sleep-related breathing disorders 42
OSA syndrome 18 (43)
Emergent central sleep apnea syndrome 14 (33)
Central sleep apnea syndrome 10 (24)
Values expressed as No. (% of diagnostic category) or No.Interestingly, IPAP of up to 25 cm H2O (median, 18;
IQR, 16-21) and EPAP up to 14 cm H2O (median, 7;
IQR, 5-10) were tolerated with nasal pillows, without
excessive leaks. There was no association between choice
of interface and leaks or AHI reported by ventilator
software (AHI; mean  SD; facial masks: 3.6  5.5/h;
nasal masks: 3.9  5.4/h; nasal pillows: 4.8  7.3/h, P ¼
.33) (e-Figs 3A, 3B).
Other Adjuncts to NIV: Oxygen, Humidifier, and
Use of Mechanical Insufflation/Exsufflation Device
All indications combined, 40% of patients received
oxygen supplementation and 350 (72%) had a
humidifier. Supplemental oxygen was most frequently
prescribed in COPD (76%). Twenty patients used a
mechanical insufflation/exsufflation device (NMD: n ¼
16, severe COPD: n ¼ 3, KYPH: n ¼ 1).
Daily Use of Ventilator
Average daily use of NIV was high in all diagnostic
groups (missing values: n ¼ 30) (Fig 4, Table 5). Only 35284 Original Researchsubjects (8%, 454 values recorded) used their device
< 3.5 h/d. By multivariable analysis (e-Table 7), we
found no association between time spent on ventilator
and prior use of CPAP, implementation as outpatient
vs inpatient, choice of interface, major comorbidities, or
age. Time spent on NIV was lower in patients with OHS
and SRDB, and in subjects treated chronically with
opioids. Conversely, time spent on ventilator increased
with duration of treatment.
e-Figure 3B shows average daily use of NIV according to
interface used: 430  193 min with facial masks, 488 
256 min with nasal masks, and 439  192 min with
nasal pillows (P ¼ .264).Comments on Specific Groups
COPD (Including Patients With Overlap Syndrome,
n [ 190): BMI: Fourteen patients (7%) had a BMI
# 18 kg/m2. Conversely, 90 (47%) were obese. Twenty-
nine percent had concomitant OSAS. Follow-up PaCO2
without NIV (n ¼ 169) was # 6 kPa in 76 subjects
(45%), # 6.5 kPa in 108 subjects (64%), and $ 8 kPa in
12 subjects (7%) (21 missing values).
Patients With OHS (n [ 127): PaCO2 (39 missing
values): PaCO2 without NIV (n ¼ 88) was # 6 kPa in
60 subjects (68%), # 6.5 kPa in 76 subjects (86%), and
$ 8 kPa in one subject.
Very Dependent Patients (Use of NIV > 16 h/d): Ten
patients (median age, 63 years; IQR, 36-70; 60% men;
median BMI, 19 kg/m2; IQR, 16-24) used their ventilator
> 16 h/d (median, 1'222min; IQR, 1'093-1'309): seven had
NMD (amyotrophic lateral sclerosis and Duchenne
muscular dystrophy), two had COPD, and one had KYPH.
Implementation and Follow-up
NIV was initiated electively in 247 subjects (50%) vs in
an emergency setting for 220 (45% of all patients; not
specified for 22 patients; 5%). Most patients were started
on NIV as inpatients (n ¼ 400; 82%) vs 73 (15%) as
outpatients (not specified for 16 patients; 3%). Initiating
NIV in an outpatient setting was more frequent in
subjects with SRBDs (45% of total), OHS (21%), and
NMDs (17%).
One-third (n ¼ 174; 36%) of all patients were followed
exclusively by a pulmonologist in private practice. All
other subjects were followed either by one of the four
hospitals participating in this study (n ¼ 243; 49%), or
cooperatively by a pulmonologist and a hospital center
(n ¼ 72; 15%). Most patients were followed at least on a[ 1 5 8 # 1 CHE S T J U L Y 2 0 2 0 ]








(%) 489 (100) 135 (28) 55 (11) 79 (16) 127 (26) 29 (6) 22 (4) 42 (9)
rometry (n ¼ 353; missing: 136)
EV1
(% predicted)
46 (31-64) 30 (22-46) 46 (34-60) 45 (34-58) 66 (52-82) (29-53) 34 (30-44) 93 (86-102)
VC
(% predicted)
62 (45-76) 64 (49-73) 69 (61-77) 44 (33-58) 69 (53-81) (30-54) 34 (30-45) 94 (87-101)
EV1/FVC
(% predicted)
83 (63-98) 54 (41-75) 76 (56-84) 98 (82-111) 97 (93-102) (83-114) 99 (77-108) 102 (92-106)

















aCO2, kPa 5.8 (5.3-6.5) 6.3 (5.7-7.1) 5.8 (5.2-6.4) 5.6 (5-6.1) 5.7 (5.3-6.3) (5.3-7) 6.2 (5.5-7.1) 5.2 (4.7-5.4)
aO2,
a kPa 9 (8-9.9) 8 (6.9-8.9) 8.8 (7.9-9.4) 9.8 (8.3-11) 9 (8.4-9.7) (8.1-9.8) 9.3 (8.9-10.3) 10.6 (9.8-
10.9)
CO3











a % 93.6 (91.3-
95.6)




93.5 (92-95) (90.9-96) 93.4 (93-97.2) 96 (95-96.8)
turnal pulse oximetry (n ¼ 350; missing: 139)
ean SpO2, % 92.6 (90.2-94) 92.3 (90-94) 91.4 (88.9-93) 93.2 (91-95.3) 91.6 (89.3-
93.4)




7.3 (3.2-13.8) 6.8 (2.9-11) 7.4 (4.2-12.1) 5.6 (2-11.2) 9.9 (5.8-16) 3.7-16.8) 4.4 (1.7-15) 6.9 (3.7-18.7)
turnal capnography (n ¼ 153; missing: 336)
ean PtcCO2, kPa 6.2 (5.6-6.8) 6.4 (5.6-6.9) 6.2 (5.8-6.8) 5.7 (5.2-6.7) 6.1 (5.5-6.7) (5.5-6.6) 6 (5.7-6.8) 6 (5.8-6.2)
oxygen desaturation index. See Table 1 legend for expansion of other abbreviations.










































TABLE 4 ] Ventilator Modes, Interfaces, and Other Adjuncts to NIV
Modes, Interfaces












479 (98)a 135 (100) 55 (100) 71 (90) 127 (100) 28 (96.5) 20 (91) 42 (100)
Spontaneous/
timed mode
407 (83) 115 (86) 46 (84) 63 (80) 107 (84) 27 (93) 20 (91) 29 (71)
iVAPS mode 29 (6) 12 (9) 4 (7) 4 (6) 8 (6) 1 (3.5) . .
AVAPS-AE
mode
20 (4) 5 (4) 3 (5) 2 (2) 10 (8) . . .




11 (2)b . . 8 (10)b . 1 (3.5) 2 (9) .
VAC mode 5 (1) . . 2 (3) . 1 (3.5) 2 (9) .
PC mode 4 (0.8) . . 4 (6) . . . .
PS mode 1 (0.2) . . 1 (1) . . . .
Interfaces
Facial mask 359 (73) 115 (85) 45 (82) 44 (56) 96 (76) 15 (52) 16 (73) 28 (67)
Nasal mask 91 (19) 12 (9) 7 (13) 22 (28) 27 (21) 11 (38) 4 (18) 8 (19)
Nasal pillows 40 (8) 8 (6) 3 (5) 15 (19) 3 (2) 3 (10) 2 (9) 6 (14)
Other adjuncts to NIV
Oxygen 196 (40) 103 (76) 22 (40) 7 (9) 40 (31) 11 (38) 11 (50) 2 (5)
Humidifier 350 (72) 107 (79) 43 (78) 58 (73)c 86 (68) 20 (69) 13 (59) 24 (57)
Values listed are the most recent values obtained. Values are expressed as No. (%). AVAPS-AE ¼ average volume assured pressure support-automatic
expiratory positive airway pressure; iVAPS ¼ intelligent volume-assured pressure support; Other modes ¼ autospontaneous/timed, VAuto, or sponta-
neous modes; PC ¼ pressure control ventilation; PS ¼ pressure support ventilation; VAC ¼ volume assist-control ventilation. See Table 1 legend for
expansion of other abbreviations.
aMissing data: n ¼ 3.
bMissing data: n ¼ 1.
cMissing data: n ¼ 2.yearly basis: 88% (n ¼ 431) had been evaluated within
the preceding 12 months.
When compared with hospital-based follow-ups,
patients followed by pulmonologists in private practice
had their treatment initiated more often as outpatients
(27% vs 9%) and were more often on bilevel positive
pressure devices in spontaneous/timed mode
(91% vs 80%). Pulmonologists in private practice tended
to follow a higher percentage of patients with OHS (55
of 174, 32% vs 72 of 315, 23%) and SRBD (22 of 174,
13% vs 20 of 315, 6%), whereas patients with NMD were
managed more frequently by hospitals (59 of 315,
19% vs 20 of 174, 11%). Number of comorbidities,
average daily use of ventilator, and correction of SRDBs
did not differ significantly between subjects with a286 Original Researchhospital-based or a liberal pulmonologist-based follow-
up.Discussion
This study is to our knowledge the largest detailed
descriptive report of an unselected population of
subjects treated by long-term NIV. Patients were on
average in their 70s, with a slight male preponderance;
most were obese and had several comorbidities. They
were almost exclusively ventilated with bilevel pressure
support ventilators in spontaneous/timed mode, and
used their ventilator approximately 7 h/d. Most patients
had their treatment initiated in a hospital setting (82%),
with only one-half in an emergency situation. Adherence
to treatment was on average excellent, with 8% of[ 1 5 8 # 1 CHE S T J U L Y 2 0 2 0 ]
TABLE 5 ] Ventilator Settings According to Modes
Settings, AHI, and Compliance All Patients COPD
Overlap
Syndrome NMD OHS Kyphoscoliosis Other RLDs SRBD
No. (%) 489 (100) 135 (28) 55 (11) 79 (16) 127 (26) 29 (6) 22 (4) 42 (9)
Bilevel ventilators, ST mode (n ¼ 407)
IPAP, cm H2O
a 18 (16-21) 18 (16-20) 20 (18-22) 15 (13-18) 21 (18-24) 17 (16-20) 18 (16-20) 17 (15-18)
EPAP, cm H2O
a 7 (5-10) 6 (5-7) 8 (7-10) 5 (4-7) 10 (7-11) 6 (5-8) 6 (5-7) 10 (7-12)
BURR, cycles/minb 14 (12-17) 14 (12-16) 16 (14-18) 14 (12-16) 14 (12-18) 14 (14-16) 15 (13-17) 14 (12-16)
Bilevel ventilators, volume-targeted modes (n ¼ 49)
ResMed devices 29 (6) 12 (9) 4 (7)c 4 (5)c 8 (6) 1 (3)c 0 (0) 0 (0)
Targeted VA, L/mind 5.2 (5.2-5.2) 5.2 (5.2-5.2) . . 5.2 (5.2-5.5) . . .
Targeted RR, cycles/
mina
15 (13-15) 15 (13.5-15) . . 14 (13-15) . . .
Philips Respironics
devices
20 (4) 5 (4) 3 (5)c 2 (2)c 10 (13) 0 (0) 0 (0) 0 (0)









5 (4.5-5.9) 5.1 (5-6) . . 4.7 (4.2-5) . . .
Bilevel positive pressure ventilators, ResMed (n ¼ 381; 78% of total) and Lowenstein Medical devices (n ¼ 11, 2% of total)
AHI, No./h 1.5 (0.4-4.1) 1 (0.3-3) 2.1 (1.2-5) 1.8 (0.5-4.6) 1.3 (0.3-3.1) 2.2 (0.1-4.7) 0.8 (0.2-1.8) 4.9 (1.6-9.4)








511 (446-672) 368 (298-454)
Bilevel positive pressure ventilators, Philips Respironics devices (n ¼ 87; 18% of total)
AHI, No./h 3.4 (1.8-9.1) 3.3 (1.5-3.9) 2.6 (1.7-3.3) 3.8 (3-7.9) 6.7 (1.8-10) 3.5 (2.6-7.1) 1.9 (1.8-2.4) 9.3 (8.5-10.6)








579 (473-595) 322 (287-347)
Values listed are the most recent values obtained. Values are expressed as median (interquartile range) or No. (%). See e-Tables 4, 5 for further details and data provided by ventilator software. Results are presented
separately according to manufacturer of device because settings, software, and data presentation differ. AHI ¼ apnea-hypopnea index; BURR ¼ backup respiratory rate; EPAP ¼ expiratory positive airway pressure;
IPAP ¼ inspiratory positive airway pressure; NMD ¼ neuromuscular disease; RR ¼ respiratory rate; ST ¼ spontaneous/timed; VA ¼ alveolar volume; VT ¼ tidal volume.
aMissing data: n ¼ 2.
bMissing data: n ¼ 3.
cValues are not reported because of a limited number of patients.










patients (n ¼ 35) only using their device < 3.5 h. Patient
follow-up was either hospital-based or performed by a
private practitioner (pulmonologist) with minor
differences between populations followed and no
significant difference in terms of end points, such as
AHI or average daily use of NIV.
Prevalence of NIV in our area (presently 37.9 per
100,000 inhabitants) has increased 2.5-fold over the last
18 years.3 These figures are similar to those reported by
European countries with a national registry: 47 per
100,000 inhabitants in Norway (2019, Norwegian
National registry for long-term ventilation), 33 per
100,000 inhabitants in Sweden (2018 report, Swedevox),
and 39.5 per 100,000 inhabitants in Finland (2018).22 To
put these results in perspective, the Eurovent study, a

















(10%) n = 19
























Figure 3 – A, Distribution of ventilator modes used by the 489 patients
studied. See e-Table 3 for details. B, Distribution of interfaces used by the
489 patients studied. ST ¼ spontaneous/timed.
288 Original Researchcountries and 27,118 users, estimated prevalence of NIV
to be 6.6 per 100,000 inhabitants.23
COPD (n ¼ 190, including overlap syndrome) is now by
far the most important group of patients treated by
home NIV in this area: they represent 39% of all patients
included (as opposed to 27.5% in 2000). They are in
their early 70s (Table 1), with no sex predominance,
comorbid, most often overweight (n ¼ 35; 18%) or obese
(n ¼ 90; 47%), and have severe or very severe airway
obstruction. Twenty-nine percent had concomitant
OSAS (overlap syndrome). They have the same
phenotype as those described as being the most frequent
cause of noniatrogenic acute hypercapnic respiratory
failure leading to invasive or noninvasive ventilation in
the ICU.24 Almost all patients were on bilevel positive
pressure ventilators in a spontaneous/timed mode (n ¼
161; 85%), and only 24 (13%) used volume-targeted
modes. Two-thirds (n ¼ 125; 66%) had supplemental
oxygen. Interestingly, average inspiratory pressures
(IPAP: 18.7  4 cm H2O) were slightly lower than in the
multicentric German randomized controlled trial by
Kohnlein et al25 (IPAP: 21.6  4.7 cm H2O). In spite of
this, median values for daytime PaCO2 were within the
targets set by Kohnlein et al25 and average compliance
was actually higher (7.6  3.0 vs 5.9  3.0 h) in the
present study. Comparisons are however merely
indicative: this was not a prospective cohort, but a group
of patients treated by NIV for a median of 39 months
(IQR, 14-73), with a possible selection of the more
compliant subjects overtime.
OHS was the second group of importance and included
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Figure 4 – Distribution of average daily use of ventilator in 454 patients
with data available from ventilator software. See Figure 1 legend for
expansion of abbreviation.
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late 60s (Table 1), with a slight male predominance, and
a high rate of metabolic syndromes (n ¼ 53; 42%). Most
patients were on bilevel positive pressure ventilators in a
spontaneous/timed mode (n ¼ 107; 84%), and only 18
(14%) used volume-targeted modes. Pressure settings
were similar to those reported in the Pickwick study;
however, in this multicentric Spanish study, a volume-
targeted mode was used.26 Median compliance was > 6
h/d (6.3  2.7 h), with only 13 patients (10%) using their
device < 3.5 h/d. Residual AHI (according to device
software) was normalized in most cases.
The medical literature shows that CPAP can be as
efficient as NIV in OHS, even in the presence of severe
hypercapnia,27-29 and guidelines have only been updated
recently.30 The data in our study do not allow to
determine if there is already in our area a substantial
proportion of patients with OHS who are treated
initially by CPAP. Our impression is that this will be an
important change in the near future.
Interfaces and AHI
A high proportion of patients (73%) used facial masks.
This proportion reached 85% in COPD.31 Although
physicians are increasingly aware of the impact of facial
masks on upper airway resistance under CPAP or
NIV,32 studies report a high use of facial masks in
chronic NIV. For instance, a survey by Callegari et al31
reported a 77% use of facial masks in a real-life study of
long-term NIV in COPD. In that report, use of facial
masks increased when NIV had been initiated after an
acute exacerbation, with higher IPAP and lower BMI.
Some authors suggest that, historically, especially in
COPD, nasal masks were the default option in older
studies because of lower insufflation pressures.33 Several
other groups have reported a more frequent use of facial
vs nasal masks or even a default use of facial masks in
long-term NIV.34-36 Full face masks were also the default
option in the Pickwick study of NIV in OHS.37
AHI reported by ventilator software was low for all
diagnostic categories, without any significant difference
according to interface used. Use of AHI as a surrogate
measurement for polygraphic or polysomnographic
assessment is debated, but three independent studies
have shown a satisfactory agreement between AHI
obtained with ventilator software and PSG
assessment.38-40 Choice of interface was not associated
with significant differences in average daily use of
ventilator or residual AHI reported by ventilator
software.chestjournal.orgModes
Autotitrating modes were seldom used in this
observational study (16%). Interestingly, although a plug
and play type of option may seem more appealing to
pulmonologists in private practice, this option was used
in fact more often in one hospital center, irrespective of
the underlying diagnosis. These modes have not yet
convinced ventilator prescribers in this area: indeed, the
available data suggest that they do at most as well as
usual settings.6,7,9-14,41-43 Volume-cycled ventilators and
volume assist-control modes have virtually disappeared,
confirming the trend previously described.3
Initiation and Follow-up
Most new NIV treatments were initiated as in-patients.
For 45% of the population, NIV was started after an
acute episode of hypercapnic respiratory failure. There is
a trend in favor of increasing implementation of NIV on
an outpatient basis, especially in SRBDs, OHS, and
NMDs. The limitations are mainly related to availability
of beds in day care structures with trained health-care
workers.
It is a specificity of Switzerland that pulmonologists in
private practice can prescribe, initiate, and follow
patients with chronic hypercapnic respiratory failure put
on NIV, alone or with a health-care provider. For
patients followed by pulmonologists in private practice,
NIV had been more frequently initiated on an
outpatient basis; there were minor differences as to
choice of modes, but no significant differences as to
diagnoses, comorbidities, number of patients seen
within the preceding 12 months, or end points such as
AHI or average daily use of NIV.
Modalities of follow-up were in agreement with the
SomnoNIV16 recommendations, and polygraphy or
polysomnography are not routine procedures in this
population. Routine monitoring includes the following:
(1) targeted clinical assessment, (2) ABGs, (3) nocturnal
pulse oximetry, and (4) synthesis report from ventilator
software. Nocturnal capnography is limited for
outpatients in Switzerland because there is no consensus
on reimbursement for home nocturnal capnography.
Study Limitations
There are several limitations to this study. First, it is a
purely observational study; therefore, data presented
cannot be used to validate or support the indication or
efficacy of NIV in any of the patient groups we analyzed.
However, the large number of unselected subjects, and289
the fact that most patients have spent several years
under NIV, with a good adherence to their treatment,
supports the modes and settings of NIV, which are
described. Second, there are missing values in follow-up
tests: these result from the real-life design of this study,
and allow to appreciate how these patients are followed
in an area which is familiar with the use of NIV since the
mid-1980s. Third, data reported concerning AHI and
average daily use of NIV must be considered as
describing a selection of patients who have pursued and
accepted their treatment for at least 3 months, and most
often for several years: this is not a cohort study, and
noncompliant or less compliant subjects who may have
interrupted their treatment before 3 months are not
reported. Fourth, these observations may not be
representative of other regions of the world where
demographics (BMI, ethnicity, and socioeconomic290 Original Researchstatus) differ. Finally, choice of devices, settings,
interfaces, oxygen supplementation, and follow-up tests
performed relied entirely on the attending physician(s).Conclusions
In this large observational study of home NIV, COPD is
presently the most important group of patients, followed
by those with OHS. Prevalence of NIV has increased 2.5-
fold since 2000. Patients are on average in their 70s, with
frequent comorbidities; more than one-half are obese,
and approximately 30% are > 75 years of age. Devices
used are almost exclusively pressure-cycled, with a low
use of volume-targeted and autotitrating modes. Results
in terms of control of PaCO2, AHI, and average daily use
were similar to those published in the randomized
controlled trials concerning COPD and OHS.Acknowledgments
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